← Leaderboards
Emmanuel S. Antonarakis
Johns Hopkins University
$741,150
Attributed
$1,482,300
Total exposure
1
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $370.6K · FY2015–18$500K$375K$250K$125K$0
'15
'16
'17
'18
Funding mix
By agency
NIH$1,482,300 · 1
By mechanism
R01$1,482,300 · 1
Top collaborators
- Jun Luo4 shared
Most similar at Johns Hopkins University
Same institution · by research overlap
- Samuel R Denmeade$5,431,317
- Stanley R Hamilton$26,840,413
- Chetan Bettegowda$9,213,403
- Kenneth J. Pienta$43,861,680
- Arlene A Forastiere$3,988,680
Others in their field
Top investigators on “Follow-Up”
- Jeffrey P Krischer · University Of South Florida$398,381,597
- James Dennis Neaton · Northwestern University$283,212,546
- Gregory H Reaman · National Childhood Cancer Foundation$201,951,987
- Judith S Hochman · New York University School Of Medicine$125,409,158
- Mark R Farfel · Hugo W. Moser Res Inst Kennedy Krieger$119,981,780
- David R. Weir · University Of Michigan At Ann Arbor$119,885,186
Research focus
Follow-UpFeedingAbirateroneDrug ResistanceEnrollmentAutomobile DrivingBaseAblationAndrogen ReceptorBlood SpecimenAndrogensAftercareCastration Resistant Prostate CancerClinically RelevantClinically SignificantClinical ManagementBiopsyCollectionCorrelation StudiesBloodDesignDetectionDimerFuture
Grant awards (4)
The aberrant androgen receptor underlies abiraterone/enzalutamide resistance$370,575
R01 · FY2018 · CA
The aberrant androgen receptor underlies abiraterone/enzalutamide resistance$370,575
R01 · FY2017 · CA
The aberrant androgen receptor underlies abiraterone/enzalutamide resistance$370,575
R01 · FY2016 · CA
The aberrant androgen receptor underlies abiraterone/enzalutamide resistance$370,575
R01 · FY2015 · CA